Navigation Links
China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance
Date:10/14/2008

HARBIN, China, Oct. 14 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (NASDAQ: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it started production at Peng Lai Jin Chuang Company ("Jin Chuang"), a pharmaceutical company that it acquired, on October 14, 2008.

Jin Chuang, a subsidiary of China Sky One Medical, develops, manufactures, and distributes pharmaceutical, medicinal and diagnostic products in China. It owns rights to develop and market a portfolio of twenty drugs approved by State Food and Drug Administration (SFDA) of the PRC for the treatment of colds, cardiovascular disease, and depression. Jin Chuang's products include Chinese health remedies such as Oyster Shell Calcium Tablets for the treatment of osteoporosis, and Naftoipidil Dispersible Tablets for the treatment of benign prostatic hyperplasia. China Sky One Medical completed the acquisition of Jin Chuang on September 5, 2008, for approximately $7.1 million, consisting of cash and stock. Production at Jin Chuang is moving smoothly and according to the Company's schedule.

"We are pleased to have started production at Jin Chuang, which will allow us to enhance our product line and increase our manufacturing capabilities and profitability," said Mr. Yan-qing Liu, Chairman, CEO and President of China Sky One Medical. "We expect Jin Chuang to contribute $3-$5 million to sales in fiscal 2008, and approximately $0.95-$1.55 million in net profit for the year. We believe the acquisition will increase our financial performance even further in 2009 as we scale up our production. As a result of Jin Chuang's contribution, we are reaffirming our previous full year 2008 guidance, which was provided on September 25, 2008."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio- Engineering Company Limited, and Heilongjiang Tianlong Pharmaceutical, Inc., the Company manufactures and distributes over-the- counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For further information, please contact:

China Sky One Medical, Inc.

Mr. Yu-bo Hao

Board Secretary

Tel: +86-0451-5399-4069

Email: china_sky_one@yahoo.cn

Investor Relations Contact:

Mr. Crocker Coulson

President

CCG Investor Relations

Tel: +1-646-213-1915


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Medicine to Showcase Bethin Weight Loss Product at 2008 Natural Products Expo East Trade Show
2. China Yingxia International, Inc. Announces $2 Million Share Repurchase Program
3. China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
4. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
5. Covance Decides to Pursue Its Original Preclinical Strategy in China
6. China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income
7. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
8. tootoo.com: Chinas Farmers Welcome the New Trend of Organic Farming
9. China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification
10. China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%
11. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... to bring innovative medical technologies, services and solutions to the healthcare market. The ... implementation of various distribution, manufacturing, sales and marketing strategies that are necessary to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):